[go: up one dir, main page]

ATE190660T1 - Verbesserte impfstoffe - Google Patents

Verbesserte impfstoffe

Info

Publication number
ATE190660T1
ATE190660T1 AT92904089T AT92904089T ATE190660T1 AT E190660 T1 ATE190660 T1 AT E190660T1 AT 92904089 T AT92904089 T AT 92904089T AT 92904089 T AT92904089 T AT 92904089T AT E190660 T1 ATE190660 T1 AT E190660T1
Authority
AT
Austria
Prior art keywords
improved vaccines
vaccines
improved
mutations
bacteria
Prior art date
Application number
AT92904089T
Other languages
English (en)
Inventor
Samuel I Miller Iii
John J Mekalanos
Original Assignee
Gen Hospital Corp
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Harvard College filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE190660T1 publication Critical patent/ATE190660T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255Salmonella (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42Salmonella
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT92904089T 1990-12-18 1991-12-18 Verbesserte impfstoffe ATE190660T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62960290A 1990-12-18 1990-12-18
PCT/US1991/009604 WO1992011361A1 (en) 1990-12-18 1991-12-18 Improved vaccines

Publications (1)

Publication Number Publication Date
ATE190660T1 true ATE190660T1 (de) 2000-04-15

Family

ID=24523687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92904089T ATE190660T1 (de) 1990-12-18 1991-12-18 Verbesserte impfstoffe

Country Status (6)

Country Link
EP (1) EP0563311B1 (de)
JP (1) JP3367950B2 (de)
AT (1) ATE190660T1 (de)
CA (1) CA2097931C (de)
DE (1) DE69132058D1 (de)
WO (1) WO1992011361A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599537A (en) * 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
TW201794B (de) * 1991-05-03 1993-03-11 American Cyanamid Co
EP0659086B1 (de) * 1992-09-04 1998-11-11 The University of Saskatchewan Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
DE4333742A1 (de) * 1993-10-04 1995-04-06 Klaus Prof Dr Linde Lebendimpfstoff mit erhöhter Stabilität
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
AU737981B2 (en) * 1996-09-06 2001-09-06 Australian Wool Research & Promotion Organisation Iron regulated promoter and uses thereof
NZ334649A (en) * 1996-09-06 2000-08-25 Australian Wool Res & Promotio Iron regulated promoter derived from an aerobactin gene promoter
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1012232B1 (de) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
WO2002016440A2 (en) 2000-08-25 2002-02-28 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
EP1343894A4 (de) 2000-11-02 2005-05-04 Univ Singapore Aopb-gen, -protein, homologe, fragmente und varianten davon und ihre verwendung bei der zelloberflächenpräsentation
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US10828362B2 (en) * 2012-12-07 2020-11-10 Elanco Tiergesundheit Ag Preparation of live vaccines
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
AU645489B2 (en) * 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
WO1992017785A1 (en) * 1991-03-29 1992-10-15 The General Hospital Corporation Detection of salmonella

Also Published As

Publication number Publication date
WO1992011361A1 (en) 1992-07-09
EP0563311A1 (de) 1993-10-06
JP3367950B2 (ja) 2003-01-20
EP0563311A4 (en) 1995-08-09
DE69132058D1 (de) 2000-04-20
CA2097931C (en) 2003-07-29
CA2097931A1 (en) 1992-06-19
JPH06505383A (ja) 1994-06-23
EP0563311B1 (de) 2000-03-15

Similar Documents

Publication Publication Date Title
DE69132058D1 (de) Verbesserte impfstoffe
DE69105907D1 (de) Sterilisiervorrichtung.
DE69200471D1 (de) Luftsterilisator.
DE59105798D1 (de) Bestrahlungseinrichtung.
DK0512017T3 (da) Vacciner
DE69109817D1 (de) Blockierbares Knochenplattensystem.
DE69233269D1 (de) Gas-sterilisierung
DE69100581D1 (de) Phonochirurgische Einrichtungen.
MX9100051A (es) Mezcla esterilizante y metodo de esterilizacion
DE59106795D1 (de) Wegwerfhöschen zur Erziehung.
DE69111349D1 (de) Winkeldetektor-Apparat.
DE69114856D1 (de) Infrarotstrahlungsquelle.
FR2661820B1 (fr) Clip de sterilisation.
FI912060A0 (fi) Med aktiv stroemavbrytning foersedd spaenningsregulator.
DE59107831D1 (de) Ionenquelle
DE59100118D1 (de) Abschliessbarer muellbehaelter.
DE59108045D1 (de) Medizinisches Desinfektionsgerät
DE59103806D1 (de) Lecksuchgerät.
DE69111421D1 (de) Berührungslose Kopiersteuerungseinheit.
DE59200618D1 (de) Absperrvorrichtung.
DE59202012D1 (de) Absperrdichtung.
DE69103824D1 (de) Patientenliegetische.
DE69102120D1 (de) Absperrvorrichtung.
DE68918189D1 (de) Neisseria-Vakzine.
DE59101080D1 (de) Kombinationsgerät zur Bodenbearbeitung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties